Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Odonate Therapeutics, Inc is a biotechnology business based in the US. Odonate Therapeutics shares (ODT) are listed on the NASDAQ and all prices are listed in US Dollars. Odonate Therapeutics employs 134 staff and has a market cap (total outstanding shares value) of USD$572.1 million.
|Latest market close||USD$16.31|
|52-week range||USD$12.56 - USD$46.5|
|50-day moving average||USD$15.0329|
|200-day moving average||USD$26.5375|
|Wall St. target price||USD$35|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.461|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||N/A|
|1 month (2020-11-02)||N/A|
|3 months (2020-09-02)||N/A|
|6 months (2020-06-02)||N/A|
|1 year (2019-12-02)||N/A|
|2 years (2018-12-02)||N/A|
|3 years (2017-12-02)||N/A|
|5 years (2015-12-02)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-37.55%|
|Return on equity TTM||-69.31%|
|Market capitalisation||USD$572.1 million|
TTM: trailing 12 months
There are currently 2.5 million Odonate Therapeutics shares held short by investors – that's known as Odonate Therapeutics's "short interest". This figure is 19.2% up from 2.1 million last month.
There are a few different ways that this level of interest in shorting Odonate Therapeutics shares can be evaluated.
Odonate Therapeutics's "short interest ratio" (SIR) is the quantity of Odonate Therapeutics shares currently shorted divided by the average quantity of Odonate Therapeutics shares traded daily (recently around 244992.52427184). Odonate Therapeutics's SIR currently stands at 10.3. In other words for every 100,000 Odonate Therapeutics shares traded daily on the market, roughly 10300 shares are currently held short.
However Odonate Therapeutics's short interest can also be evaluated against the total number of Odonate Therapeutics shares, or, against the total number of tradable Odonate Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Odonate Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Odonate Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1559% of the tradable shares (for every 100,000 tradable Odonate Therapeutics shares, roughly 156 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Odonate Therapeutics.
Find out more about how you can short Odonate Therapeutics stock.
We're not expecting Odonate Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Odonate Therapeutics's shares have ranged in value from as little as $12.56 up to $46.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Odonate Therapeutics's is 0.6174. This would suggest that Odonate Therapeutics's shares are less volatile than average (for this exchange).
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments. The company was founded in 2013 and is based in San Diego, California.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.